Literature DB >> 19759113

Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging.

Michael S Hofman1, Nigel C Smeeton, Sheila C Rankin, Tom Nunan, Michael J O'Doherty.   

Abstract

UNLABELLED: Many studies demonstrate a high accuracy for PET in staging lymphoma, but few assess observer variation. This study quantified agreement for staging lymphoma with PET/CT.
METHODS: The PET/CT images of 100 patients with lymphoma who had been referred for staging were reviewed by 3 experienced observers, with 2 observers reviewing each series a second time. Ann Arbor stage and individual nodal and extranodal regions were assessed. Weighted kappa (kappa(w)) and intraclass correlation coefficient were used to compare ratings.
RESULTS: Intra- and interobserver agreement was high for Ann Arbor stage (kappa(w) = 0.79-0.91), number of nodal regions involved (intraclass correlation coefficient, 0.83-0.93), and presence of extranodal disease (kappa = 0.74-0.86). High agreement was also observed for all nodal regions (kappa(w) > 0.60) except hilar (kappa(w) = 0.56-0.82) and infraclavicular (kappa(w) = 0.14-0.55). Lower agreement was observed for bowel involvement (kappa(w) = 0.37-0.71).
CONCLUSION: Experienced observers had a high level of agreement using PET/CT for lymphoma staging, supporting its use as a robust noninvasive staging tool. Further research is needed to evaluate observer variability for restaging during and after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759113     DOI: 10.2967/jnumed.109.064121

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

2.  High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.

Authors:  Raghava Kashyap; Eddie Lau; Anupkumar George; John F Seymour; Stephen Lade; Rodney J Hicks; Michael S Hofman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

Review 3.  Influences on PET Quantification and Interpretation.

Authors:  Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe
Journal:  Diagnostics (Basel)       Date:  2022-02-10

4.  Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time.

Authors:  Alin Chirindel; Krishna C Alluri; Abdel K Tahari; Muhammad Chaudhry; Richard L Wahl; Martin A Lodge; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2015-01       Impact factor: 7.794

5.  Rare case of Primary Pulmonary Extranodal Non-Hodgkin's Lymphoma in a Patient with Sjogren's Syndrome: Role of FDG-PET/CT in the Initial Staging and Evaluating Response to Treatment.

Authors:  Gonca Bural; Judith Joyce; James Ohr
Journal:  Mol Imaging Radionucl Ther       Date:  2012-12-20

6.  Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.

Authors:  Christiaan Schiepers; Magnus Dahlbom
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

7.  Evaluation of an Automatic Classification Algorithm Using Convolutional Neural Networks in Oncological Positron Emission Tomography.

Authors:  Pierre Pinochet; Florian Eude; Stéphanie Becker; Vijay Shah; Ludovic Sibille; Mathieu Nessim Toledano; Romain Modzelewski; Pierre Vera; Pierre Decazes
Journal:  Front Med (Lausanne)       Date:  2021-02-26

8.  Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy.

Authors:  Joan Fledelius; Azza Khalil; Karin Hjorthaug; Jørgen Frøkiær
Journal:  EJNMMI Res       Date:  2016-09-22       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.